Skip to content
Telix
-
Telix signs USD4.3 billion partnership with Regeneron to expand next-generation precision oncology
The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.